Micrograph of prostatic adenocarcinoma, conventional (acinar) type, the most common form of prostate cancer. Credit: Nephron / commons.wikimedia.org.

ConcertAI’s TeraRecon has integrated Bot Image’s prostate cancer (PCa) screening and detection/diagnosis platform into its Eureka clinical artificial intelligence (AI) platform.

In July last year, Bot Image received clearance from the US Food and Drug Administration (FDA) for PCa screening and detection/diagnosis.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

With the integration, the Eureka platform enables clinicians to access advanced AI and deep learning technology to support precise prostate cancer identification and diagnosis through biparametric magnetic resonance imaging (bpMRI) and AI.

ConcertAI CEO Dr Jeff Elton said: “Prostate cancer is so devasting to men around the world, and bringing a solution that aims to provide AI-driven analysis that may improve the accuracy and speed of prostate cancer detection and diagnosis is critical.

“We look forward to making ProstatID available to all of our customers and their patients.”

ProstatID, which is Bot Image’s AI and MRI post-processing software for prostate cancer, is intended to enhance the accuracy of PCa identification and diagnosis.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

 Bot Image demonstrated the software’s ability to optimise prostate cancer identification while reducing false positives.

Furthermore, ProstatID is suitable for use as a regularly planned screening mechanism to provide active surveillance for monitoring disease progression.

Bot Image CEO Dr Randall Jones said: “With a global installed base of about 1,900 health sites, TeraRecon represents a significant and immediate distribution opportunity for the unique analysis capabilities of Bot Image’s prostate solutions.

“We are thrilled to be a part of the TeraRecon AI partner ecosystem and to offer our solutions on the Eureka Clinical AI Platform and to all healthcare providers needing these services in a streamlined and best-in-breed ecosystem that TeraRecon offers.”